A Phase III, Observer-Blind, Randomized, Non-influenza Vaccine Comparator-Controlled, Parallel-Group, Multi-Country Study in Children Aged 6-35 Months to Assess the Safety and Efficacy of Abbott's Candidate Quadrivalent Influenza Vaccine
Latest Information Update: 29 May 2022
At a glance
- Drugs Influenza vaccine quadrivalent Abbott Biologicals (Primary) ; Hepatitis A vaccine; Meningococcal vaccine group C conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate; Tick-borne encephalitis vaccine; Varicella zoster virus vaccine live
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Biologicals BV
- 18 Dec 2021 This trial has been completed in Italy and Croatia, according to European Clinical Trials Database record.
- 22 Apr 2020 This trial has been completed in Denmark and Slovakia, according to European Clinical Trials Database record.
- 04 Apr 2020 This trial has been completed in Hungary according to European Clinical Trials Database.